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Aim To evaluate the effect of ginkgolide B treatment on 
vascular endothelial function in diabetic rats.
Methods The study included four groups with 15 male 
Sprague-Dawley rats: control group; control group treat-
ed with ginkgolide B; diabetic group; and diabetic treat-
ed with ginkgolide B. The activity of superoxide dismutase 
(SOD), malondialdehyde content, and nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase subunits, 
and glutathione peroxidase 1 (GPX1) protein expression 
were determined in aortic tissues. Vasoconstriction to phe-
nylephrine (PHE) and vasorelaxation to acetylcholine (Ach) 
and sodium nitroprusside (SNP) were assessed in aortic 
rings. Nitric oxide (NO) and hydrogen sulfide (H2S) were 
measured, as well as cystathionine γ lyase (CSE) and cys-
tathionine β synthetase (CBS) protein expression, and en-
dothelial nitric oxide synthase (eNOS) activity.
Results Diabetes significantly impaired PHE-induced va-
soconstriction and Ach-induced vasorelaxation (P < 0.001), 
reduced NO bioavailability and H2S production (P < 0.001), 
SOD activity, and GPX1 protein expression (P < 0.001), and 
increased malondialdehyde content and NADPH oxidase 
subunits, and CSE and CBS protein expression (P < 0.001). 
Ginkgolide B treatment improved PHE vasoconstriction 
and Ach vasorelaxation (P < 0.001), restored SOD (P = 0.005) 
and eNOS (P < 0.001) activities, H2S production (P = 0.044) 
and decreased malondialdehyde content (P = 0.014). Vas-
orelaxation to SNP was not significantly different in control 
and diabetic rats with or without ginkgolide B treatment. 
Besides, ginkgolide B increased GPX1 protein expression 
and reduced NADPH oxidase subunits, CBS and CSE pro-
tein expression.
Conclusion Ginkgolide B alleviates endothelial dysfunc-
tion by reducing oxidative stress and elevating NO bio-
availability and H2S production in diabetic rats.
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Diabetes mellitus is an endocrine disease caused by de-
creased insulin secretion or action, leading to impaired 
glucose and lipid metabolism (1). The most dangerous 
complication of diabetes mellitus is cardiovascular dis-
ease, which is the primary factor leading to high mortality 
and morbidity in diabetic patients (2). A critical role in dia-
betic cardiovascular complications is played by endothe-
lial dysfunction. Mechanisms responsible for endothelial 
dysfunction are still poorly understood, but hyperglyce-
mia-induced oxidative stress is hypothesized to be one of 
them (3). Increased blood glucose increases reactive oxy-
gen species (ROS) production via glucose auto-oxidation 
(4) and variation in activity of oxidoreductases, such as NA-
DPH oxidase (5). ROS can impair vascular function by dam-
aging endothelial cells, thus playing an important role in 
diabetes and its cardiovascular complications (6). NADPH 
oxidase is important because it generates ROS (7,8). Gluta-
thione peroxidase 1 (GPX1) is one of the pivotal antioxidant 
enzymes in vascular endothelium, which protects against 
the presence of coronary artery disease (9). Its overexpres-
sion reduces ROS formation and enhances phosphoryla-
tion of endothelial nitric oxide synthase (eNOS), which im-
proves endothelial function (10).
Hydrogen sulfide (H2S) was previously considered only 
as a toxic gas, but recent studies have suggested that 
it plays a variety of important physiological and phys-
iopathological roles (11,12). H2S is generated from L-
cysteine by several enzymes including cystathionine γ 
lyase (CSE) and cystathionine β synthetase (CBS). Some 
studies have shown that H2S takes part in modulation of 
cardiovascular system (13,14). It has also been shown that 
H2S biosynthesis is impaired in diabetes, and that it may 
be effective to administer different H2S donors to diabetic 
animals (15,16).
The risk of endothelial dysfunction is increased by sus-
tained progression of hyperglycemia and hyperlipidemia. 
Endothelial dysfunction is characterized by alterations of 
endothelium-dependent vascular response to vasocon-
strictors and vasodilators in diabetic animals (17,18). There-
fore, cardiovascular complications including endothelial 
dysfunction in patients with diabetes have been treated 
by decreasing blood glucose and lipid content, and reduc-
ing activation of angiotensin. However, these treatments 
have not prevented the development of complications 
(19), emphasizing the need for novel approaches.
Ginkgolide B, a plant-derived terpenoid, is one of natural 
bioactive components from the extract of ginkgo biloba 
leaves. Many studies have demonstrated that ginkgolide B 
can inhibit platelet-activating factor (PAF)-induced platelet 
activation via binding with PAF receptor (20,21). Therefore, 
ginkgolide B is widely used as a natural antagonist of PAF 
and inhibitor of PAF-induced inflammatory reaction (22). It 
has been shown that ginkgolide B regulates many physi-
ologic functions, including the antioxidant function, im-
proving the cognitive functions of central nervous system 
(23,24), repressing atherosclerosis (25), and abating liver 
cirrhosis (26). In this study, we investigated the effects of 
ginkgolide B on endothelial function and mediators such 
as hydrogen sulfide (H2S), biomarkers of oxidative stress, 




Sixty 8-10 weeks old male Sprague-Dawley rats (180-220 
g) were purchased from the central animal laboratory of 
Wannan Medical College. All experimental procedures 
were approved by the Academic Experimental Animal 
Care and Use Committee of Wannan Medical College. Ani-
mals received a standard pellet diet and water ad libitum, 
and were raised for 2 weeks in a standard animal laboratory 
at 22 ± 2°C temperature and with a 12-hour daylight cycle 
for acclimatization before the experiment.
After 12 hours of fasting, thirty rats were intraperitoneal-
ly injected STZ (65 mg/kg) dissolved in 0.1 mol/L natrium 
citricum buffer (pH 4.5) for induction of diabetes mellitus. 
Thirty control rats were injected with the same volume 
buffer. All rats received a standard chow and water. After 72 
hours of STZ treatment, blood was drawn from the tail vein 
to measure the levels of the fasting blood glucose for con-
firmation of diabetes mellitus. Rats with the fasting glucose 
values >15 mmol/L were regarded as diabetic and used for 
further experiments.
experimental protocol and treatment
After diabetes was confirmed, control and diabetic rats 
were randomly divided into four groups as follows: a) con-
trol group (CG, n = 15): rats received standard food and wa-
ter; b) control treated group (CT, n = 15): rats were treated 
with 5 mg/kg/d ginkgolide B and received standard food 
and water; c) diabetic group (DG, n = 15): rats received 
standard food and water; d) diabetic treated group (DT, 
n = 15): rats were treated with 5 mg/kg/d ginkgolide 
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B and received standard food and water. Ginkgolide B was 
given orally by gavage for 8 weeks.
Biochemical analyses of blood samples
At the end of the experiment, body weight was measured, 
and blood specimens were collected into prechilled test 
tubes. To assess the change of blood glucose and serum 
lipid profiles, blood specimens were centrifugated at 
1300 × g for separation of serum. Concentrations of serum 
lipid profiles were determined by the enzymatic colori-
metric methods (commercial kits from Nanjing Jiancheng 
Bioengineering Institute, Nanjing, China).
Measurement of oxidative stress, eNos activity, and 
nitric oxide (No) production
After eight weeks of ginkgolide B treatment, rats were 
anesthetized with sodium pentobarbital and euthanized, 
and blood samples and aortic tissues were immediately 
collected. For oxidative stress analysis, aortic tissue was 
homogenized and centrifugated at 13 000 × g for 10 min-
utes at 4°C. The supernatants were used to analyze redox 
enzyme activity (superoxide dismutase) and peroxidation 
production of lipid (malonaldehyde). eNOS activity and NO 
production in the supernatant were determined by enzy-
matic colorimetric methods (commercial kits from Nanjing 
Jiancheng Bioengineering Institute).
determination of H2s
H2S production in the aorta tissue was determined as pre-
viously described (27). Aorta tissues were collected and 
homogenized in an ice-cold lysis buffer (potassium phos-
phate buffer 100 mmol/L pH7.4, Na3VO4 10 mmol/L). Ho-
mogenates (250 μL) were mixed with 20 μL pyridoxal 5’-
phosphate, 20 μL L-cysteine, and 30 μL normal saline in 
sealed Eppendorff tubes and incubated at 37şC. CCl3COOH 
(10%, 250 μL), zinc acetate (1%, 250 μL), and 0.5 mL borate 
buffer (pH 10.01) were placed one by one in the tubes after 
40 minutes. The mixture was incubated with N,N-dimeth-
ylphenylendiamine sulfate (20 mM, 133 μL) in 7.2 mol/L HCl 
and FeCl3 (30 mmol/L, 133 μL) in 1.2 mol/L HCl at 37°C for 
30 minutes. The H2S production was determined by mea-
suring the absorbance of final solution at 670 nm. Plasma 
determination of H2S was performed without addition of 
L-cysteine according to above-mentioned method.
Vascular reactivity to vasoconstrictor and vasodilator 
were measured in aortic rings, which are commonly 
used as a model of vasomotoricity (28). Briefly, after animals 
were sacrificed, the thoracic aortas were immediately har-
vested, and blood and surrounding connective tissue was 
cleared away in the plate filled with Krebs-Henseleit buffer 
(KH buffer, pH 7.4) with sodium chloride (118 mmol/L), po-
tassium chloride (4.7 mmol/L), monopotassium phosphate 
(1.2 mmol/L), magnesium sulfate (1.2 mmol/L), sodium bi-
carbonate (25 mmol/L), glucose (5.5 mM), and calcium 
chloride (2.5 mmol/L). The aortas were carefully cut into 
3-4 mm aortic rings. The endothelial layer was removed in 
certain experiments so that the effects of the endothelium 
on vascular responses can be observed. The arterial rings 
were fixed in the tissue chamber with KH buffer with ac-
cess to 95% O2 and 5% CO2 gas mixtures at 37°C, and were 
connected to tension sensor and stainless wire in the bot-
tom of the chamber.
After 60 minutes equilibration, concentration-dependent 
vasoconstriction to phenylephrine (PHE, α-adrenoceptor 
agonist) was observed. To estimate the effect of ginkgolide 
B on the endothelium-dependent relaxation, vessels were 
preconstricted with 10−6 mol/L PHE, and concentration-
dependent vascular responses to acetylcholine (Ach) and 
sodium nitroprusside (SNP, nitric oxide donor) were ex-
amined. The integrity of the endothelium was verified by 
determining the endothelium-dependent vasodilation to 
Ach after contraction to PHE (10−6 mol/L). To determine the 
effects of eNOS and cyclooxygenase, vascular rings were 
pre-incubated in the KH buffer with or without Nω-nitro-
l-arginine methyl-ester (L-NAME, non-specific NOS inhibi-
tor, 100 μmol/L) or methylene blue (MB, cGMP inhibitor, 
10 μmol/L) for 20 minutes before the addition of PHE. The 
changes of contract tension to PHE were recorded. Vascu-
lar relaxation to Ach and SNP was expressed as percentage 
from submaximal constriction to PHE.
Western blotting
To analyze expression of redox enzyme, aortic tissues were 
harvested and homogenized in a prechilled buffer with Tris-
HCl (20 mmol/L), Na3VO4 (1 mmol/L), Na4P2O7 (2.5 mmol/L), 
phenylmethylsulfonyl fluoride (2 mmol/L), EDTA (1 mmol/L), 
EGDA (1 mmol/L), and protease inhibitor mixture (10 μg/
mL). Homogenates were centrifugated. Proteins in the su-
pernatants were electrophoretically separated on 8% stack-
ing gel and following 12% separation gel of sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis transferred 
onto nitrocellulose membrane. Membranes were incubated 
with blocking buffer containing Tris-HCl (20 mmol/L), NaCl 
(500 mmol/L), Tween-20 (0.1%), non-fat milk (5%) to block 
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non-specific sites and incubated with rabbit polyclonal CBS, 
CSE, GPX-1, NOX-2, NOX-4, β-actin antibody dissolved in the 
blocking buffer (1:500) overnight at 4 °C. Membranes were 
incubated with horseradish peroxidase-conjugated anti-
rabbit IgG antibody after 3 washing steps (20 mmol/L Tris, 
500 mmol/L NaCl, 0.1% Tween-20) for 1 hour. After having 
been rinsed with wash buffer for three times, the reaction 
was visualized by DAB.
statistical analysis
The values are presented as means ± standard error of the 
mean. Differences between the groups were analyzed 
with one way analysis of variance (ANOVA) using least sig-
nificance difference and t test. The analysis was performed 
with SPSS, 16.0 (SPSS Inc., Chicago, IL, USA). A P value of less 
than 0.05 was considered statistically significant.
ResuLts
Animal characteristics
Diabetic and diabetic treatment groups showed signifi-
cantly higher blood glucose levels than control groups 
(P < 0.001), which did not change after ginkgolide B treat-
ment (Table 1). Diabetic group had lower body weight 
than control group, and ginkgolide B significantly alle-
viated the decline in diabetic group (P < 0.001) (Table 1). 
Diabetic group had higher levels of total cholesterol, trig-
lycerides, and low density lipoprotein (LDL) and lower lev-
els of high-density lipoprotein (HDL) than control group 
(P < 0.001) (Table 1). Ginkgolide B treatment significantly 
reduced cholesterol (P < 0.001), triglycerides (P = 0.029), 
tABLe 1. effects of ginkgolide B (5 mg/kg) on biochemical profile (n = 10 per group)*
Control group Control treatment group diabetic group diabetic treatment group
Body weight (g) 331 ± 10.4 327 ± 11.2 179 ± 11.7† 228 ± 15.9‡
Blood glucose (mmol/L) 4.63 ± 0.58 4.76 ± 0.61 26.31 ± 3.77† 24.53 ± 3.14
Total cholesterol (mmol/L) 2.19 ± 0.47 1.97 ± 0.36 6.20 ± 0.82† 4.16 ± 0.72‡
Triglycerides (mmol/L) 1.51 ± 0.37 1.43 ± 0.35 3.05 ± 0.88† 2.18 ± 0.48‡
Low density lipoprotein (mmol/L) 2.32 ± 0.45 2.11 ± 0.42 5.28 ± 1.22† 3.56 ± 0.62‡
High-density lipoprotein (mmol/L) 1.14 ± 0.20 1.19 ± 0.12 0.47 ± 0.12† 0.68 ± 0.17‡
*Results are expressed as mean ± standard error of the mean.
†P < 0.001 compared with control group.
‡P < 0.05 compared with diabetic group, in particular P < 0.001 compared with diabetic group for body weight and total cholesterol, P = 0.029 for 
triglycerides, P = 0.011 for low density lipoprotein, P = 0.003 for high-density lipoprotein.
tABLe 2. superoxide dismutase (sod) activity and malondialdehyde (MdA) content in aortas of control and diabetic rats treated 
with or without ginkgolide B (5 mg/kg). data are expressed as mean ± standard deviation (n = 8 per group)
Control group Control treatment group diabetic group diabetic treatment group
Activity of SOD(U/mg protein) 193.69 ± 11.80 190.41 ± 11.17 137.08 ± 10.46* 153.10 ± 8.68†
Content of MDA(nmol/ mg protein) 1.23 ± 0.13 1.17 ± 0.14 2.02 ± 0.33* 1.62 ± 0.24†
*P < 0.0001, compared with control group.
†P < 0.05 compared with diabetic group
FiGuRe 1. Glutathione peroxidase 1 (GPX 1) and nicotinamide adenine 
dinucleotide phosphate (NAdPH) oxidase protein expression in aortas of 
control and diabetic rats treated or not treated with ginkgolide B (5 mg/kg). 
(A) Representative Western blots (upper panel) and quantitative analysis 
(lower panel) for GPX 1; (B) Representative Western blots (upper panel) and 
quantitative analysis (lower panel) for NoX2 and NoX4. CG – control group; 
Ct – control treated group; dG – diabetic group; dt – diabetic treated group. 
Results are expressed as mean ± standard error of the mean. the number of 
animals per group was 8. *P < 0.05 compared with control group; #P < 0.05 
compared with diabetic group.
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and LDL (P = 0.011) concentrations, but elevated HDL 
(P = 0.003) concentration in diabetic rats (Table 1).
Antioxidant effects of ginkgolide B
The activity of SOD was decreased (137.09 ± 10.46 vs 
193.69 ± 11.80 U/mg,, P < 0.001) and malondialdehyde con-
tent was increased (2.02 ± 0.33 vs 1.23 ± 0.13 nmol/mg, 
P < 0.001) in diabetic compared with control rats. Gink-
golide B significantly decreased malondialdehyde content 
(1.64 ± 0.24 vs 2.02 ± 0.33 nmol/mg, P = 0.014) and elevated 
SOD activity (153.10 ± 8.68 vs 137.09 ± 10.46 U/mg, P = 0.005) 
in diabetic rats (Table 2). Oxidases Nox2 and Nox4 protein ex-
pression was significantly elevated in diabetic groups com-
pared with control rats (Figure 1B), while antioxidase GPX 1 
level was reduced (Figure 1A). Ginkgolide B decreased the 
expression of Nox2 and Nox4 proteins and increased expres-
sion of GPX 1 protein in diabetic rats (Figure 1A, 1B).
tABLe 3. effects of ginkgolide B on nitric oxide (No) production and activity of endothelial nitric oxide synthase (Nos) in control and 
diabetic rats treated with or without ginkgolide B (5 mg/kg). data are expressed as mean ± standard deviation (n = 8 per group)
Control group Control treatment group diabetic group diabetic treatment group
NO production (μmol/g protein) 8.43 ± 0.93 8.26 ± 1.26 2.62 ± 1.02* 6.34 ± 1.36†
NOS activity (U/g protein) 565.3 ± 57.0† 552.5 ± 77.3† 232.3 ± 24.4† 495.99 ± 59.1†
*P < 0.0001, compared with control group.
†P < 0.001 compared with diabetic group.
tABLe 4. effects of ginkgolide B on the maximum response to PHe incubated with or without L-NAMe or MB (5 mg/kg) (n = 8 per 
group)*†
PHe (mol/L) induced contraction response (%)
10-8 10−7 10−6 10−5
Control group No incubation 17.89 ± 2.25  44.73 ± 4.52  75.13 ± 10.12  98.77 ± 5.35
L-NAME 26.92 ± 3.91‡  72.06 ± 7.18§ 107.89 ± 12.79§ 126.80 ± 10.87§
MB 55.70 ± 5.61§ 108.13 ± 14.62§ 123.29 ± 12.63§ 146.91 ± 10.25§
Control treatment group No incubation 17.44 ± 2.01  40.83 ± 4.12  78.71 ± 6.81  99.60 ± 11.02
L-NAME 29.92 ± 4.63ǁ  70.80 ± 6.87ǁ 104.88 ± 9.27ǁ 127.67 ± 11.48ǁ
MB 52.28 ± 6.49ǁ 102.92 ± 13.85ǁ 116.15 ± 12.05ǁ 146.16 ± 12.27ǁ
Diabetic group No incubation 25.69 ± 3.39‡  61.89 ± 7.56§  99.77 ± 12.65§ 120.04 ± 9.69§
L-NAME 33.10 ± 6.49††  68.04 ± 7.13 105.64 ± 12.15 126.82 ± 11.01
MB 51.54 ± 8.37††  94.52 ± 12.35†† 112.23 ± 11.58** 134.89 ± 10.84
Diabetic treatment group No incubation 21.23 ± 3.30**  52.59 ± 7.74††  82.35 ± 5.95†† 104.21 ± 8.58††
L-NAME 35.51 ± 3.13¶  71.95 ± 4.14¶ 123.21 ± 8.30¶ 126.66 ± 11.31¶
MB 58.08 ± 6.63¶ 102.30 ± 7.41¶ 118.63 ± 8.76¶ 144.56 ± 11.01¶
*L-NAMe – L-NG-nitro-l-arginine methyl ester; MB – methylene blue; PHe – phenylephrine. No incubation – vascular rings were pre-incubated in the 
KH buffer without L-NAMe and MB for 20 min before the addition of PHe; L-NAMe – vascular rings were pre-incubated in the KH buffer with L-NAMe 
for 20 min before the addition of PHe; MB – vascular rings were pre-incubated in the KH buffer with MB for 20 min before the addition of PHe.
†Results are expressed as mean ± standard error of the mean.
‡P < 0.05 or §P < 0.01 compared with control group (no incubation).
iiP < 0.01 compared with control treatment (no incubation).
¶P < 0.01 compared with diabetic treatment (no incubation).
**P < 0.05 or ††P < 0.01 compared with diabetic group (no incubation).
tABLe 5. effects of ginkgolide B and endothelial removal on the maximum response to phenylephrine (PHe) (5 mg/kg) (n = 8 per 
group)*
Control group Control treatment group diabetic group diabetic treatment group
Endothelium intact(g) 0.81 ± 0.20 0.86 ± 0.32 1.45 ± 0.30† 1.09 ± 0.23‡
Endothelium removed(g) 2.59 ± 0.44§ 2.53 ± 0.48§ 2.40 ± 0.34§ 2.43 ± 0.37§
*Results are expressed as mean ± standard error of the mean.
†P < 0.01 compared with control group.
‡P < 0.05 compared with diabetic group.
§P < 0.01 compared with endothelium intact ring.
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effect of ginkgolide B on No production and Nos activity
NO production was decreased (2.62 ± 1.02 vs 8.43 ± 0.93 
μmol/g, P < 0.001) and eNOS activity was reduced 
(232.27 ± 24.44 vs 565.34 ± 56.97 U/g, P < 0.001) in diabetic 
rats compared with control rats. Ginkgolide B significantly 
improved NO production (6.34 ± 1.36 vs 2.62 ± 1.02 μmol/g, 
P < 0.001) and reduced eNOS activity (495.99 ± 59.06 vs 
232.27 ± 24.44 U/g, P < 0.001) in diabetic rats (Table 3).
effect of ginkgolide B on vascular reactivity
Diabetic rats had reduced vasorelaxation to Ach compared 
with control rats (the maximum response [Rmax]: 44.8 ± 6.4 
vs 92.2 ± 7.9%, P < 0.001) (Figure 2A), but there were no 
significant differences in vasorelaxation to SNP between 
all groups (Rmax: 93.7 ± 7.5 vs 90.8 ± 6.2%, P = 0.691) (Figure 
2C). Vasoconstriction to PHE was higher in diabetic than 
in control rats (Rmax: 120.0 ± 9.7 vs 98.8 ± 5.4%, P < 0.001) 
(Figure 2B). The impaired vasorelaxation to Ach was im-
proved (Rmax: 69.1 ± 9.4 vs 98.8 ± 5.4%, P < 0.001) and the 
increased vasoconstriction to PHE was reduced in dia-
betic rats compared with diabetic treatment rats (Rmax: 
104.2 ± 10.6 vs 120.0 ± 9.7%, P = 0.007). Vasodilatations to 
Ach and vasoconstriction to PHE were not changed in con-
trol treatment rats.
effects of ginkgolide B on endothelial, cGMP, and No 
modulation of PHe-induced contraction
In all groups except diabetic group, vascular rings incubat-
ed with L-NAME or MB showed an increase in maximum 
response to PHE compared with not-incubated vascular 
rings. L-NAME or MB did not change the maximum re-
sponse to PHE in diabetic controls (Table 4). Absence of 
endothelial cells increased the maximum responses to PHE 
compared with the presence of endothelial cells, and max-
imum vasoconstriction to PHE was not different among all 
the groups in the absence of endothelial cells (Table 5).
effect of ginkgolide B on H2s
Diabetic rats exhibited a progressive reduction in H2S plas-
ma levels (Figure 3A) and diabetes significantly impaired the 
ability to convert L-cysteine into H2S (Figure 3B). Ginkgolide 
B significantly increased H2S plasma levels in diabetic rats 
(Figure 3A) and enhanced the ability to convert L-cysteine 
into H2S (Figure 3B). Western blot analysis was performed to 
evaluate the effect of ginkgolide B on expression of CBS and 
CSE. The expression of CBS and CSE was significantly up-
regulated in diabetic rats compared with control rats (Fig-
ure 3C, 3D). However, the expression of CBS and CSE was 
significantly down-regulated in diabetic treatment rats 
compared with diabetic rats (Figure 3C, 3D).
FiGuRe 2. effects of ginkgolide B on vascular reactivity to 
acetylcholine (A), phenylephrine (B), and sodium nitroprusside 
(sNP) (C). CG – control group; Ct – control treated group; dG 
– diabetic group; dt – diabetic treated group. *P < 0.05 com-
pared with control group; #P < 0.05 compared with diabetic 
group. data are expressed as mean ± standard deviation. n = 8 
rats for each group.
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disCussioN
In this study, we provide evidence that ginkgolide B atten-
uated the progressive endothelial and vascular dysfunc-
tion in diabetic rats by increasing antioxidant and improv-
ing vascular regulation and prevented the development of 
vascular dysfunction by increasing the expression of CBS 
and CSE.
Ginkgolides are terpenoids from the extract of ginkgo bi-
loba leaves, which are widely used as natural antagonist of 
PAF to reduce platelet activation (29). Ginkgolide B exhib-
ited the strongest inhibition of platelet activation (20,21). 
Hyperglycemia impairs vasorelaxation and vasoconstric-
tion by damaging vascular endothelial cells (30,31). In-
creased levels of serum lipids in diabetes increase the risk 
of complications (32). A previous study showed that gink-
golide B ameliorated plasma cholesterol and/or HDL levels 
(29), while this study showed that it decreased the levels of 
cholesterol, triglycerides, and LDL, and elevated HDL levels 
in diabetic rats. HDL has been shown to exhibit cardiopro-
tective effect (33) and sphingosine-1-phosphate, a constit-
uent of HDL, improved endothelial function and caused 
NO-dependent vasorelaxation (34). Our results showed 
that diabetic rats had improved lipoperoxidation, as con-
firmed by increased malondialdehyde level and decrease 
in activity of antioxidant enzyme as SOD. Furthermore, we 
observed reduced antioxidase GPX 1 level and elevated 
oxidase Nox2 and Nox4 levels.
Ginkgolide B exhibits an antioxidant effect via scavenging 
peroxy radicals (28,29,35-37), as well as reduces reactive 
oxygen species and malondialdehyde levels, supporting 
its antioxidant role (38,39). We also observed that it down-
regulated GPX1 and increased Nox2 and Nox4 protein ex-
pressions, as well as SOD activity in diabetic rats.
Recent studies have shown that ginkgolide B protects en-
dothelial cells and inhibits atherosclerosis plaque (25,40). 
Similarly, our study showed that it improved both vasore-
laxation to Ach and vasoconstriction to PHE in diabetic rats, 
which may be related to increase in eNOS activity and NO 
production. NO is a critical factor for regulation of vascu-
lar responses, and endothelial dysfunction may be related 
to the decrease in NO production in STZ-induced diabetic 
rats (41). We also observed that the endothelium-indepen-
dent vasorelaxation to SNP was not significantly different 
between diabetic and control groups, and that ginkgolide 
B treatment did not change vasorelaxation. Furthermore, 
we assessed the impact of L-NAME (eNOS inhibitor) or MB 
(cGMP inhibitor) pretreatment on vasoconstriction to PHE. 
The maximum response to PHE was increased in control, 
treatment control, and diabetic treatment group, but it was 
not changed in the diabetic group. These results suggest-
ed that ginkgolide B improved endothelial function possi-
bly by reducing impairment of endothelium and enhanc-
ing eNOS activity. Therefore, the mechanisms underlying 
the ability of ginkgolide B to prevent endothelial dysfunc-
tion could involve an enhanced NO bioactivity, leading to 
improved endothelium-dependant vascular responses.
A recent study suggested that the H
2S pathway was in-
volved in vascular dysfunction in diabetic mice (42). Our 
results showed that H2S level in diabetic rats was reduced, 
FiGuRe 3. effects of ginkgolide B on hydrogen sulfide (H2s) content in 
plasma, H2s production and cystathionine β synthetase (CBs) and cys-
tathionine γ lyase (Cse) protein expression in the artery. (A) H2s plasma 
levels; (B) H2s production (C) Representative Western blots (upper panel) 
and quantitative analysis (lower panel) for CBs; (D) Representative West-
ern blots (upper panel) and quantitative analysis (lower panel) for Cse. 
CG – control group; Ct – control treated group; dG – diabetic group; dt 
– diabetic treated group. Results are expressed as mean ± standard error 
of the mean. the number of animals per group was 8. *P < 0.05 compared 
with control group; #P < 0.05 compared with diabetic group.
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but that the expression of CBS and CSE protein was up-
regulated, which is consistent with previous results (15). 
Furthermore, treatment with ginkgolide B increased H2S 
level and down-regulated the expression of CBS and CSE 
protein. H2S is known as a gasotransmitter with protective 
effects in various tissue injuries (42-44). It is easily oxidized 
by reaction with oxygen and free radicals (45,46). A recent 
study showed that H2S released from Na2S increased en-
dothelial NO production through Akt activation and sub-
sequently increased phosphorylation of eNOS at Ser1177 
(47). Therefore, the increase in CBS and CSE protein ex-
pression can be a compensatory response resulting from 
oxidative stress induced by hyperglycemia, and oxidative 
stress-reduced H2S production. Ginkgolide B elevated H2S 
level by improving oxidative stress, which increased NO 
production.
In summary, this study demonstrated that treatment with 
ginkgolide B attenuated the progressive endothelial and 
vascular dysfunction in diabetic rats. The protective effect 
of ginkgolide B on endothelial function may result from its 
inhibition of oxidative stress and modulation of NO and 
H2S production in the aorta of diabetic rats.
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